{"id":"shr-1701-capox","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Immune-related adverse events (e.g., pneumonitis, hepatitis)"},{"rate":null,"effect":"Neutropenia"},{"rate":null,"effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL5095383","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"SHR-1701 blocks the PD-L1 checkpoint, preventing tumor cells from suppressing T-cell responses, thereby restoring anti-tumor immunity. When combined with CAPOX chemotherapy, the regimen delivers both direct cytotoxic effects and enhanced immunological attack against cancer cells. This combination approach is designed to improve efficacy in solid tumors, particularly gastric and colorectal cancers.","oneSentence":"SHR-1701 is a PD-L1 inhibitor combined with CAPOX chemotherapy (capecitabine and oxaliplatin) to enhance anti-tumor immunity while delivering cytotoxic chemotherapy.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:34:27.372Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer or gastroesophageal junction cancer (in combination with CAPOX)"},{"name":"Colorectal cancer (in combination with CAPOX)"}]},"trialDetails":[{"nctId":"NCT07478731","phase":"PHASE2","title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Hong Qiu","startDate":"2025-12-20","conditions":"CRC (Colorectal Cancer)","enrollment":48},{"nctId":"NCT07384234","phase":"PHASE2","title":"SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis","status":"NOT_YET_RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-01-31","conditions":"Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","enrollment":60},{"nctId":"NCT07294664","phase":"PHASE2","title":"PD1/TGFβ In Combination With EZH2 And Chemotherapy For First - Line Treatment Of Gastric Cancer","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2025-06-15","conditions":"Advanced Gastric Cancer, SHR1701","enrollment":36},{"nctId":"NCT04950322","phase":"PHASE3","title":"A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","startDate":"2021-12-06","conditions":"Gastric or Gastroesophageal Junction Cancer","enrollment":737}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SHR-1701、CAPOX","genericName":"SHR-1701、CAPOX","companyName":"Suzhou Suncadia Biopharmaceuticals Co., Ltd.","companyId":"suzhou-suncadia-biopharmaceuticals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SHR-1701 is a PD-L1 inhibitor combined with CAPOX chemotherapy (capecitabine and oxaliplatin) to enhance anti-tumor immunity while delivering cytotoxic chemotherapy. Used for Gastric cancer or gastroesophageal junction cancer (in combination with CAPOX), Colorectal cancer (in combination with CAPOX).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}